Propranolol hydrochloride

Propranolol Hydrochloride is the hydrochloride salt form of the classical beta‑adrenergic receptor antagonist (β‑blocker) with antianginal, antiarrhythmic, and antihypertensive properties . Propranolol Hydrochloride competitively antagonizes beta‑adrenergic receptors, inhibiting beta‑adrenergic reactions and reducing heart rate, cardiac output, and myocardial oxygen demand . Propranolol Hydrochloride is indicated for the management of hypertension, angina pectoris, cardiac arrhythmias, migraine prophylaxis, and essential tremor, and has additional applications in anxiety management and thyrotoxicosis . Propranolol Hydrochloride is a USP‑referenced compound with a defined monograph specifying a purity of 98.0%–101.5% (on dried basis) . As the prototypical β‑blocker, Propranolol Hydrochloride remains a cornerstone therapeutic agent and a widely used reference standard in pharmaceutical quality control, analytical method development, and pharmacopoeial testing .

Product Parameters

Synthetic Route

1-Naphenol undergoes a hydrocarbonation reaction with epichlorohydrin to yield 3-(1-naphthoxy)-1,2-epoxypropane; this intermediate then undergoes an opening ring reaction with isopropylamine to form propranolol; finally, it reacts with hydrochloric acid to form Propranolol Hydrochloride.

Pharmacokinetics

Propranolol Hydrochloride Tablets: After oral administration, this drug is completely absorbed from the gastrointestinal tract, extensively metabolized in the liver, with a bioavailability of approximately 30%; caution is advised when used in patients with hepatic impairment. The peak plasma concentration is reached within 1–1.5 hours after administration; the elimination half-life ranges from 2 to 3 hours; and the plasma protein binding rate is 90%–95%. Individual plasma concentrations exhibit significant variability, with an apparent volume of distribution of (3.9 ± 6.0) L/kg. The drug is excreted renally, primarily as metabolites, with a small proportion (<1%) excreted as the parent compound. It cannot be eliminated via dialysis.

Propranolol Hydrochloride Injection: This product exhibits a high plasma protein binding rate of 93%. The half-life (T₁/₂) of the intravenous injection formulation is 2–3 hours. It is excreted renally, primarily as metabolites; only a small proportion (<1%) is excreted in its unchanged form, and it cannot be eliminated via dialysis.

Why Cosperpharm?

When your pharmaceutical quality control, analytical method development, or generic formulation work requires high‑quality Propranolol Hydrochloride, Cosperpharm delivers with the analytical rigor and documentation support that pharmaceutical customers demand.

USP‑aligned quality for regulatory confidence. Propranolol Hydrochloride has a well‑established USP monograph specifying purity of 98.0%–101.5% on dried basis, melting point of 163–166 °C, and specific rotation of −1.0° to +1.0° . Our analytical release protocol verifies these parameters, ensuring your reference standard or intermediate meets pharmacopoeial specifications.

Documentation that supports your regulatory submissions. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity, melting point, loss on drying, and residue on ignition data, structured for direct insertion into your method validation package.

Flexible supply for all applications. Cosperpharm supplies Propranolol Hydrochloride from gram quantities for analytical reference standards to bulk quantities for generic formulation development and commercial manufacturing.

Technical support for your development needs. Our team can advise on analytical methods for Propranolol Hydrochloride (HPLC, dissolution testing, stability studies) based on established USP methodology .

Contact Us

For high‑quality Propranolol Hydrochloride supporting your analytical development, generic formulation, or quality control needs, we are here to provide reliable supply and expert support.